Click Therapeutics, Inc.’s acquisition of Better Therapeutics, Inc.’s AspyreRx – the first FDA-authorized prescription digital therapeutic (PDT) for type-2 diabetes – among other assets, reflects the company’s growing focus on obesity and cardiometabolic disease amid the GLP-1 agonist boom.
“There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and provider capabilities,” says...







